EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder

Domenique Escobar, Chirag Doshi, Mazyar Zahir, Siamak Daneshmand

Die Urologie · 2026-02 · 65 (2) · 162-170

DOI: 10.1007/s00120-025-02625-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Die Urologie, online erschienen am 23.06.2025. Verfasst von Domenique Escobar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Catherine and Joseph Aresty Department of Urology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern Calif…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Southern California.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-risk non-muscle-invasive bladder cancer (NMIBC) is most commonly treated with Bacillus Calmette–Guérin (BCG) as first-line therapy. However, in light of the ongoing BCG shortage in the United States, a significant need exists for alternative treatment options, both in the upfront setting as well as for patients with BCG-refractory disease. While radical cystectomy remains the gold standard for patients with BCG-refractory disease, many patients are unfit or unwilling to undergo this procedure. Several new agents, many with novel mechanisms of action, have been approved or are actively being investigated in this setting. Materials and methods Articles were chosen for review based on expert knowledge of the literature as well as on PubMed literature searches for the topics of focus. Appropriate articles were selected for inclusion by reviewing article titles, abstracts, and full texts.

Results

There is ample evidence for emerging therapies in BCG-refractory NMIBC including systemic immunotherapy and various intravesical options, such as chemotherapy, gene therapy, and novel drug delivery systems. Radical cystectomy, however, remains the gold standard. Response rates and duration of response vary across treatment modalities, with complete response rates at any time ranging from 41% to 82%. Radical cystectomy should still be recommended to patients with high-risk features given the risks of recurrence, progression, upstaging, and occult lymph node metastases.

Conclusion

While radical cystectomy remains the standard of care for patients with BCG-refractory disease, many patients are unable or unwilling to undergo the procedure. Several novel therapies have been recently approved or are currently being investigated with overall promising early results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineCarcinoma, Transitional CellHumansNeoplasm InvasivenessCystectomyImmunotherapyAdjuvants, Immunologic

Stichwörter der Autor:innen

BCG-refractoryGene therapyIntravesicalNon-muscle-invasive bladder cancerRadical cystectomy

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Catherine and Joseph Aresty Department of Urology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Suite 7416, 90089, Los Angeles, CA, USA. Dom…
  • Catherine and Joseph Aresty Department of Urology, University of Southern California/Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Suite 7416, 90089, Los Angeles, CA, USA.

Förderung

  • University of Southern California

Zitieren

APA

Escobar, D., Doshi, C., Zahir, M., & Daneshmand, S. (2026). Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder. Die Urologie, 65(2), 162-170. https://doi.org/10.1007/s00120-025-02625-2

Vancouver

Escobar D, Doshi C, Zahir M, Daneshmand S. Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder. Die Urologie. 2026;65(2):162-170. doi:10.1007/s00120-025-02625-2

BibTeX
@article{Escobar2026,
  author = {Escobar, Domenique and Doshi, Chirag and Zahir, Mazyar and Daneshmand, Siamak},
  title = {Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder},
  journal = {Die Urologie},
  year = {2026},
  volume = {65},
  number = {2},
  pages = {162--170},
  doi = {10.1007/s00120-025-02625-2}
}
Kostenlos starten →